亞洲轉移性去勢療法無效前列腺癌於中國醫藥大學附設醫院以安可坦治療之預後與相關結果

蔡正晏、張議徽、王又德、蕭博任、陳冠亨、連啟舜、謝博帆、邱鴻傑、鄒頡龍、陳國樑

葉進仲、陳汶吉、張士三、黃志平、張兆祥、楊啟瑞、吳錫金

中國醫藥大學附設醫院 泌尿部

The real-world outcome with Enzalutamide in Asian men with metastatic castrate-resistant prostate cancer treated in China Medical University Hospital

Cheng-Yen Tsai, Yi-Huei Chang, Yu-De Wang, Po-Jen Hsiao, Guan-Heng Chen, Chi-Shun Lien, Po-Fan Hsieh, Hung-chieh Chiu, Chieh-Lung Chou, Kuo-Liang Chen, Chin-Chung Yeh, Wen-Chi Chen, Shih-San Chang, Chi-Ping Huang, Chao-Hsiang Chang, Chi-Rei Yang, Hsi-Chin Wu   

Divisions of Urology, China Medical University Hospital, Taichung, Taiwan

Introduction: We report the cohort study of clinical outcomes in metastatic castrate-resistant prostate cancer (mCRPC) patients treated with enzalutamide in a single-center clinical setting.

Methods: A retrospective analysis of mCRPC patients treated at China Medical University Hospital, a tertiary hospital in Taiwan, from 2004 to 2021 was conducted. Disease characteristics, treatment outcomes, subsequent treatment use, and adverse events were retrieved from electronic medical records. The primary clinical outcome was overall survival (OS). The secondary outcome included the PSA response rate, primary resistance rate, and the analysis of adverse events.

Results: Out of 75 patients with mCRPC treated with enzalutamide, with a median age of 74.9 (57-92) and years. Follow-up duration was 24.45 months. Median OS was 34.342 (95% CI, 27.942–40.743). The PSA response rate is 64.4% within three months after starting the Enzalutamide therapy. Common side effects include fatigue (13.04%), hypertension (8.7%), elevated liver enzyme (8.7%).